

DAFTAR PUSTAKA

- Apperley, J.F. 2015. Chronic myeloid leukaemia. *Lancet*. 385: 1447–1459
- Au, W. Y., Caguioa, P. B., Chuah, C., Hsu, S. C., Jootar, S., Kim, D., Kweon, I., O’Neil, W. M., Saikia, T. L., Wang, J. 2009. Chronic myeloid leukemia in Asia. *International Journal Hematology*. 89: 14-23
- Bagg, A. 2002. Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. *Journal of molecular diagnostics*. 4(1): 1-9
- Calabretta, B. and Perrotti, B. 2010. The biology of CML blast crisis. *Blood*. 103(11): 4010-4018
- Castilla, L.H. 2008. C/EBP α in leukemogenesis: a matter of being in the right place with the right signals. *Cancer Cell*. 18: 289-290
- Chang, J. S., Santhanam, R., Trotta, R., Neviani, P., Eiring, A. M., Briercheck, E., Ronchetti, M., Roy, D. C., Calabretta, B., Caligiuri, M. A., Perrotti, D. 2007. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2-dependent suppression of C/EBP α -driven myeloid differentiation. *Blood*. 110(3): 994-1002
- Clarkson, B., Strife, A., Wisniewski, D., Lambek, C. L. and Liu, C. 2003. Chronic myelogenous leukemia fas a paradigm of early cancer and possible curative strategies. *Leukemia*. 17: 1211-1262
- Dash, A.B., Williams, I.F., Kutok, J.L., Tomasson, M.H., Anastasiadou, E., Lindahl, K., Li, S., Van Etten, R.A., Borrow, J., Housman, D., Druker, B., Gilliland, D.G. 2002. A murine model of CML blast crisis induced by cooperation between BCR-ABL and NUP98/HOXA9. *Proceedings of The National Academy of Sciences of The United States of America*. 99(11): 7622-7627
- De Braekeleer, E., Douet-Guilbert, N., Rowe, D., Bown, N., Morel, F., Berthou, C., Ferec, C., De Braekeleer, M. 2011. ABL1 fusion genes in hematological malignancies: a review. *European Journal of Hematology*. 86: 361-371
- Druker, B. J. 2008. Translation of the Philadelphia chromosome into therapy for CML. *Blood*. 112(13): 4808-4815
- Dudley, D.D., Wang, H., Sun, X. 2009. Hes-1 potentiates T-cell lymphomagenesis by up-regulating a subset of Notch target genes. *Plos One*. 4(8): 1-10
- Espinosa, L., Cathelin, S., D’Altri, T., Trimarchi, T., Statnikov, A., Guiu, J., Rodilla, V., Ingle’s-Esteve, J., Nomdedeu, J., Bellosillo, B., Besses, C., Abdel-Wahab, O., Kucine, N., Shao-Chong, S., Mullighan, C.C., Levine, R.L., Rajewsky, K., Aifantis, I., Bigas, A. 2010. The Notch/Hes-1 pathway

sustains NF- κ B activation through CYLD repression in T cell leukemia. *Cancer Cell*. 18: 268-275

Fausel, C. 2007. Targeted chronic myeloid leukemia therapy: seeking a cure. *Journal of Managed Care Pharmacy*. 13(8): 8-12

Frazer, R., Irvine, A.R., McMullin, M.F. 2007. Chronic myeloid leukaemia in the 21st century. *Ulster Medical Journal*. 76(1): 8-17

Fröhling, S., Schlenk, R. F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., and Döhner, K. 2004. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. *Journal of Clinical Oncology*. 22(4): 624-631

Garcia-Manero, G., Faderl, S., O'Brien, Cortes, J., Talpaz, M., Kantarjian, H. 2003. Chronic myelogenous leukemia: A review and update of therapeutic strategies. *Cancer*. 98(3): 437-451

Handayani, W. and Haribowo, A. S. 2008. Asuhan keperawatan pada klien dengan gangguan sistem hematologi. Salemba Medika. Jakarta: 87

Hantschel, O. and Superti-Furga, G. 2004. Regulation of the c-abl and bcr-abl tyrosine kinases. *Molecular Cell Biology*. 33-43

Hehlmann, R. 2003. Current CML therapy: progress and dilemma. *Leukemia*. 17: 1010-1012

Jabbour, E., Kantarjian, H. 2014. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. *American Journal of Hematology*. 89(5): 548

Kantarjian, H. M., Baccarani, M., Jabbour, E., Saglio, G., Cortes, J. E. 2011. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. *Clinical Cancer Research*. 17(7): 1674-1681

Kato, N., Kitaura, J., Doki, N., Komeno, Y., Watanabe-Okochi, N., Togami, K., Nakahara, F., Oki, T., Enomoto, Y., Fukuchi, Y., Nakajima, H., Harada, Y., Harada, H., and Kitamura T. 2011. Two types of C/EBP mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. *Blood*. 117(1): 221-222

Kirstetter, P., Schuster, M. B., Bereshchenko, O., Moore, S., Dvinge, H., Kurz, E., Theilgaard-Moñch, K., Mañsson, R., Pedersen, T. A., Pabst, T., Schrock, E., Porse, B. O., Jacobsen, S. E. W., Bertone, P., Tenen, D. G., and Nerlov, C. 2008. Modeling of C/EBP mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. *Cancer Cell*. 13: 299-310

- Laurent, E., Talpaz, M., Kantarjian, H., and Kurzrock, R. 2011. The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis. *Cancer Research*. 61: 2343-2355
- Leroy, H., Roumier, C., Huyghe, P., Biggio, V., Fenaux, P., and Preudhomme, C. 2005. CEBPA point mutations in hematological malignancies. *Leukemia*. 19: 329-334
- Liu, Z., Dai, X. and Du, B. 2015. Hes-1: a key role in stemness, metastasis and multidrug resistance. *Cancer Biology and Therapy*. 16(3): 353-359
- Melo, J. and Chuah, C. 2008. Novel agents in CML therapy: Tyrosine kinase inhibitors and beyond. *Hematology*: 427-432
- Murata, K., Hattori, M., Hirai, N., Shinozuka, Y., Hirata, H., Kageyama, R., Sakai, T., and Minato, N. 2005. Hes-1 directly controls cell proliferation through the transcriptional repression of p27kip1. *Molecular and Cellular Biology*. 25(10): 4262-4271
- Nakahara, F., Sakata-Yanagimoto, M., Komeno, Y., Kato, N., Uchida, T., Haraguchi, K., Kumano, K., Harada, Y., Harada, H., Kitaura, J., Ogawa, S., Kurokawa, M., Kitamura, T., Chiba, S. 2010. Hes-1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. *Blood*. 115(14): 2872-2880
- Nakahara, F., Kitaura, J., Uchida, T., Nishida, C., Togami, K., Inoue, D., Matsukawa, T., Kagiya, Y., Enomoto, Y., Kawabata, K. C., Chen-Yi, L., Komeno, Y., Izawa, K., Oki, T., Nagae, G., Harada, Y., Harada, H., Otsu, M., Aburatani, H., Heissig, B., Hattori, K., Kitamura, T. 2014. Hes-1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells. *Blood*. 123(25): 3932-3942
- Nowicki, M. O., Pawlowski, P., Fischer, T., Hess, G., Pawlowski, T., Skorski, T. 2003. Chronic myelogenous leukemia molecular signature. *Oncogene*. 22: 3952-3963
- Nucifora, G., Birn, D.J., Espinosa, R., Erickson, P., LeBeau, M.M., Roulston, D., McKeithan, T.W., Drabkin, H., Rowley, J.D. 1993. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. *Blood*. 81(10): 2728-2730
- Pabst, T. and Mueller, B.U. 2009. Complexity of CEBPA dysregulation in human acute myeloid leukemia. *Clinical Cancer Research*. 15(17): 5303-5305
- Perrotti, D., Jamieson, C., Goldman, J., Skorski, T. 2010. Chronic myeloid leukemia: mechanisms of blastic transformation. *The Journal of Clinical Investigation*. 120(7): 2254-2264
- Quintas-Cardama, A., and Cortes, J. 2009. Molecular biology of bcr-abl 1-positive chronic myeloid leukemia. *Blood*. 113(8): 1619-1627

- Rana, A., Shah, S.H., Rehman, N., Ali, S., Ali, G. M., Bhatti, S., and Farooqi, A. A. 2011. Chronic myeloid leukemia: Attributes of break point cluster region-abelson (BCR-ABL). *Journal of Cancer Research and Experimental Oncology*. 3(6): 62-66
- Rumpold, H. and Webersinke, G. 2011. Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL. *Current Cancer Drug Targets*.11: 3-9
- Sakata-Yanagimoto, M., Nakagami-Yamaguchi, E., Saito, T., Kumano, K., Yasutomo, K., Ogawa, S., Kurokawa, M., Chiba, S. 2009. Coordinated regulation of transcription factors through Notch2 is an important mediator of mast cell fate. *Proceedings of The National Academy of Sciences of The United States of America*. 105(22): 7839-7840
- Saul, M.K., Stein, S., Grez, M., Jakobsson, P., Steinhilber, D., Suess, B. 2016. UPF1 regulates myeloid cell functions and S100A9 expression by the hnRNP E2/miRNA-328 balance. *Scientific Reports*. 6: 1-7
- Shet, A.S., Jahagirdar, B.N., Verfaillie, C.M. 2002. Chronic myelogenous leukemia: mechanisms underlying disease progression. *Leukemia*. 16: 1402-1411
- Skroski, T. 2012. Genetic mechanisms of chronic myeloid leukemia blastic transformation. *Curr Hematol Malig Rep*. 7: 87-93
- Siegel, R.L., Miller, K.D., Jemal, A. 2015. Cancer statistics, 2015. *Cancer Journal Clinical*. 65(1): 5-29
- Sillaber, C., Mayerhofer, M., Agis, H., Sagaster, V., Mannhalter, C., Sperr, W.R., Geissler, K., Valent, P. 2003. Chronic myeloid leukaemia: pathophysiology, diagnostic parameters, and current treatment concepts. *Wien Klin Wochenschr*. 115(13-14): 485-504
- Sobolewski, C., Cerella, C., Dicato, M., Diederich, M. 2016. Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells. *Cell Cycle*. 10(17): 2978-2993
- Sun, H., Ghaffari, S., Taneja, R. 2007. bHLH-Orange transcription factors in development and cancer. *Translational Oncogenomics*. 2: 107-120
- Tamura, T., Kurotaki, D., Koizumi, S. 2015. Regulation of myelopoiesis by the transcription factor IRF8. *International Journal of Hematology*. 101: 342-351
- Tian, C., Yu, Y., Jia, Y., Zhu, L., Zh, Y. 2015. Hes-1 activation suppresses proliferation of leukemia cells in acute myeloid leukemia. *Annual Hematology*. 94: 1477-1480

Timchenko, N. A., Wilde, M., Nakanishi, M., Smith, J. R., and Darlington, G. J. 1996. CCAAT/enhancer-binding protein (C/EBP) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. *Genes and Development*. 10: 804

Tomita, K., Hattori, M., Nakamura, E., Nakanishi, S., Minato, N., and Kageyama, R. 1999. The bHLH gene Hes-1 is essential for expansion of early T cell precursors. *Genes and Development*. 13: 1203-1210

Uchida, T., Kitaura, J., Nakahara, F., Togami, K., Inoue, D., Maehara, A., Nishimura, K., Kawabata, K. C., Doki, N., Kakihana, K., Yoshioka, K., Izawa, K., Oki, T., Sada, A., Harada, Y., Ohashi, K., Katayama, Y., Matsui, T., Harada, H., and Kitamura, T. 2014. Hes-1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. *Experimental Hematology*. 42: 369-379

Waight, J.D., Banik, D., Griffiths, E.A., Nemeth, M.J., Abrams, S.I. 2014. Regulation of the interferon regulatory factor-8 (irf-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (stat5) transcription factor in chronic myeloid leukemia. *The Journal of Biological Chemistry*. 289(22): 15642-15651

Ward, A.C., Loeb, D.M., Soede-Bobok, A.A., Touw, I.P., Friedmann, A.D. 2000. Regulation of granulopoiesis by transcription factors and cytokine signals. *Leukemia*. 14: 973-980

Zhang, P., Iwasaki-Arai, J., Iwasaki, H., Fenyus, M. L., Dayaram, T., Owens, B. M., Shigematsu, H., Levantini, E., Huettner, C. S., Lekstrom-Himes, J. A., Akashi, K. A., and Tenen, D. G. 2004. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP α . *Immunity*. 21: 853-863

Zhang, J., Han, B., Li, X., Bies, J., Jiang, P., Koller, R.P., Wolff, L. 2016. Distal regulation of c-myb expression during IL-6-induced differentiation in murine myeloid progenitor M1 cells. *Cell Death and Disease*. 7: 1-6

Zou, Q., Tan, S., Yang, Z., Wang, J., Xian, J., Zhang, S., Jin, H., Yang, L., Wang, L., Zhang, L. 2016. The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b. *Oncotarget*: 1-9